Skip to main content
. 2019 May 3;10:464. doi: 10.3389/fneur.2019.00464

Table 4.

Demographics of the 15 anti-NMDAR encephalitis with 3-month follow-up.

Anti-NMDAR encephalitis (n = 15)
Before treatment After treatment P* value
CSF anti-NMDAR Abs positive (n, %) 15 (100) 12 (80) 0.224P1
Sex (male: female) 8:7 8:7
mRS (IQR) 4 (3–5) 2 (1–2) 0.002P2
Hcy level (umol/L, IQR) 10.73 (6.36–19.97) 8.77 (2.57–12.30) 0.004P3
CRP level (mg/L, IQR)a 7 (0.65–13.45) 1 (0.60–4.90) 0.041P2

Anti-NMDAR, anti-N-Methyl-D-aspartate receptor; CSF, cerebrospinal fluid; Ab, antibody; Hcy, homocysteine; mRS, modified Rankin Scale; CRP, C-reactive protein; IQR, interquartile range. a, n = 13.

*

Chi-square test was used for testing the association of two binary variables. Paired t-test was used when comparing the Hcy levels before and after treatment, and paired Mann-Whitney U test (also known as Wilcoxon rank-sum test) was used when comparing mRS scores and CRP level before and after treatment. P* value: P1, Chi-square test; P2, paired Mann-Whitney U tests; P3, paired t-test.